Bliss GVS Pharma

What does Bliss GVS Pharma do?

Bliss GVS Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, originally founded in 1984. As of March 2025, it reported net sales of ₹198 Cr and a net profit of ₹16 Cr, with a market cap of ₹1,436 Cr.

Overview:<BR>Bliss GVS Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1984 as Bliss Chemicals & Pharmaceuticals India Private Limited. It transitioned to a Public Limited Company and changed its name to Bliss Chemicals & Pharmaceuticals India Limited, later adopting the name Bliss GVS Pharma Limited on May 12, 2006. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 198 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 16 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 1,436 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.36%<BR>- Debt Equity: -0.12<BR>- Return on Equity: 8.03%<BR>- Price to Book: 1.40<BR><BR>Contact Details:<BR>Address: 102 Hyde Park Sakivihar Road, Andheri East Mumbai Maharashtra : 400072<BR>Tel: 91-22-42160000<BR>Email: info@blissgvs.com<BR>Website: http://www.blissgvs.com

What is the bonus history of the Bliss GVS Pharma?

Bliss GVS Pharma announced a bonus issue in a ratio of 3:5, with an ex-date of September 26, 2008, and a record date of September 30, 2008. Shareholders received 3 additional shares for every 5 shares held.

Bliss GVS Pharma has a recorded bonus history where they announced a bonus issue in a ratio of 3:5. The ex-date for this bonus was on September 26, 2008, and the record date was September 30, 2008. This means that for every 5 shares held, shareholders received 3 additional shares as a bonus. If you have any more questions about the company or its financial activities, feel free to ask!

Has Bliss GVS Pharma declared dividend?

Bliss GVS Pharma Ltd has declared a 50% dividend, amounting to 0.5 per share, with an ex-date of July 18, 2024. While recent performance shows a decline in the last 6 months, total returns over the past year and two years have been positive at 36.01% and 84.95%, respectively.

Bliss GVS Pharma Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 0.5<BR>- Ex-date: Jul-18-2024<BR><BR>Dividend Yield: 0.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.24%, with a dividend return of 0%, resulting in a total return of -13.24%.<BR><BR>Over the past year, the price return was 35.54%, the dividend return was 0.47%, leading to a total return of 36.01%.<BR><BR>In the last 2 years, the price return was 83.73%, with a dividend return of 1.22%, resulting in a total return of 84.95%.<BR><BR>For the 3-year period, the price return was 62.39%, the dividend return was 1.37%, culminating in a total return of 63.76%.<BR><BR>In the last 4 years, the price return was 21.5%, with a dividend return of 1.84%, leading to a total return of 23.34%.<BR><BR>Over the past 5 years, the price return was 41.11%, with a dividend return of 2.54%, resulting in a total return of 43.65%.<BR><BR>Overall, Bliss GVS Pharma has declared a dividend, contributing positively to total returns over longer periods, particularly in the 1-year and 2-year spans, while recent performance shows a decline in the short term.

Who are the peers of the Bliss GVS Pharma?

Bliss GVS Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Themis Medicare, Lincoln Pharma, Anuh Pharma, Wanbury, and Remus Pharma. While Bliss GVS Pharma has average management and below-average growth, its 1-year return of 33.37% is better than Themis Medicare's but lower than Wanbury's 104.73%.

Peers: The peers of Bliss GVS Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Themis Medicare, Lincoln Pharma., Anuh Pharma, Wanbury, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., Anuh Pharma, Wanbury, and Remus Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Divi's Lab., Torrent Pharma, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., and Wanbury, and Average growth is noted for Anuh Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Bliss GVS Pharma, Lincoln Pharma., and Anuh Pharma, while Good capital structure is found at Torrent Pharma and Themis Medicare, and Below Average at Wanbury.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wanbury at 104.73%, while Themis Medicare has the lowest at -33.90%. Bliss GVS Pharma's 1-year return of 33.37% is significantly higher than Themis Medicare's but lower than Wanbury's. Additionally, Themis Medicare, Lincoln Pharma., and Remus Pharma have negative six-month returns.

Who are in the management team of Bliss GVS Pharma?

As of March 2023, the management team of Bliss GVS Pharma includes Vibha G Sharma (Whole-time Director), Shruti Vishal Rao (Whole-time Director), Subramanian R Vaidya (Chairman & Independent Director), Santosh Parab (Non-Executive & Independent Director), Aditi Bhatt (Company Secretary & Compliance Officer), Shilpa Bhatia (Non-Executive & Independent Director), and Gagan Harsh Sharma (Managing Director). These members are responsible for the company's governance and operations.

As of March 2023, the management team of Bliss GVS Pharma includes the following members:<BR><BR>1. Vibha G Sharma - Whole-time Director<BR>2. Shruti Vishal Rao - Whole-time Director<BR>3. Subramanian R Vaidya - Chairman & Independent Director<BR>4. Santosh Parab - Non-Executive & Independent Director<BR>5. Aditi Bhatt - Company Secretary & Compliance Officer<BR>6. Shilpa Bhatia - Non-Executive & Independent Director<BR>7. Gagan Harsh Sharma - Managing Director<BR><BR>These individuals play key roles in the company's governance and operations.

Who are the top shareholders of the Bliss GVS Pharma?

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath with 30.78%, Arian Investment Limited at 8.58%, and individual investors holding 32.63%. Additionally, 42 foreign institutional investors hold 13.18%, with no pledged promoter holdings.

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath, who holds the highest promoter stake at 30.78%. The highest public shareholder is Arian Investment Limited, with a holding of 8.58%. Additionally, individual investors collectively hold 32.63% of the shares. The company also has 42 foreign institutional investors (FIIs) with a combined holding of 13.18%, while mutual funds hold a negligible amount through two schemes. Notably, there are no pledged promoter holdings.

How big is Bliss GVS Pharma?

As of 24th July, Bliss GVS Pharma Ltd has a market capitalization of 1,656.00 Cr, with recent net sales of 809.73 Cr and a net profit of 84.30 Cr. The company reported shareholder's funds of 1,050.38 Cr and total assets of 1,300.84 Cr.

As of 24th July, Bliss GVS Pharma Ltd has a market capitalization of 1,656.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Bliss GVS Pharma reported Net Sales of 809.73 Cr and a Net Profit of 84.30 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 1,050.38 Cr and Total Assets of 1,300.84 Cr.

How has been the historical performance of Bliss GVS Pharma?

Bliss GVS Pharma has experienced steady growth in net sales and profits, with net sales increasing from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025. However, rising expenditures and liabilities pose challenges despite improvements in profit before tax and consolidated net profit.

Answer:<BR>The historical performance of Bliss GVS Pharma shows a mixed trend in financial metrics over the years.<BR><BR>Breakdown:<BR>Bliss GVS Pharma's net sales have seen a steady increase from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025, reflecting a positive growth trajectory. The total operating income also rose correspondingly, reaching INR 809.73 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 619.62 crore in March 2024 to INR 683.04 crore in March 2025, impacting the operating profit, which decreased from INR 150.62 crore to INR 126.69 crore in the same period. Despite this, the profit before tax improved from INR 116.87 crore to INR 125.64 crore, leading to a profit after tax of INR 90.26 crore in March 2025, up from INR 81.58 crore in March 2024. The consolidated net profit also increased to INR 84.30 crore in March 2025 from INR 75.45 crore in March 2024. On the balance sheet, total assets grew from INR 1,211.59 crore in March 2024 to INR 1,300.84 crore in March 2025, while total liabilities also increased, but at a slower pace, from INR 1,211.59 crore to INR 1,300.84 crore. Cash flow from operating activities showed a slight increase to INR 105 crore in March 2025, compared to INR 102 crore in March 2024, indicating stable operational cash generation. Overall, while Bliss GVS Pharma has shown growth in sales and profits, the rising costs and liabilities present challenges that the company will need to address moving forward.

Are Bliss GVS Pharma latest results good or bad?

Bliss GVS Pharma's latest results show strong revenue growth with ₹244.40 crores in Q2 FY26, but profitability has declined sharply, with a net profit drop of 36.69% from the previous quarter. Investors should be cautious due to concerns about earnings quality, leading to a current stock rating of "Hold."

Bliss GVS Pharma's latest results present a mixed picture. On one hand, the company achieved record revenue of ₹244.40 crores in Q2 FY26, reflecting a strong sequential growth of 17.80% and a year-on-year increase of 12.27%. This indicates robust demand for its pharmaceutical products.<BR><BR>However, profitability has come under significant pressure. The net profit for the quarter was ₹27.25 crores, which represents a sharp decline of 36.69% compared to the previous quarter, although it is a 12.32% increase year-on-year. The operating margins also contracted dramatically, falling to 13.0% from 19.92% in the previous quarter, raising concerns about the sustainability of profit levels.<BR><BR>Additionally, a notable portion of the profit came from other income, which constituted nearly half of the profit before tax. This reliance on non-operating income raises questions about the quality of earnings and the core operational performance of the company.<BR><BR>Overall, while the revenue growth is commendable, the significant drop in profitability and the concerns regarding earnings quality suggest that investors should approach Bliss GVS Pharma with caution. The current rating for the stock is "Hold," indicating that while there are strengths, there are also significant risks that need to be monitored closely.

Should I buy, sell or hold Bliss GVS Pharma?

Is Bliss GVS Pharma overvalued or undervalued?

As of December 4, 2025, Bliss GVS Pharma is fairly valued with a PE ratio of 16.35, outperforming the Sensex recently, while compared to peers, Sun Pharma is expensive at a PE of 37.78, and Aurobindo Pharma is also fairly valued at a PE of 20.77.

As of 4 December 2025, the valuation grade for Bliss GVS Pharma has moved from attractive to fair. The company is currently fairly valued based on its financial metrics, with a PE ratio of 16.35, an EV to EBITDA of 13.26, and a PEG ratio of 0.92. In comparison to its peers, Sun Pharma is considered expensive with a PE ratio of 37.78, while Aurobindo Pharma is also fair with a PE ratio of 20.77.<BR><BR>Despite the recent downgrade in valuation grade, Bliss GVS Pharma has shown resilience, outperforming the Sensex over the past week and month, with returns of 2.32% and 10.20%, respectively. Overall, the company appears to be fairly valued in the current market context, reflecting its competitive position within the pharmaceuticals and biotechnology industry.

Is Bliss GVS Pharma technically bullish or bearish?

As of December 4, 2025, Bliss GVS Pharma shows a strong bullish trend supported by positive MACD and Bollinger Bands indicators, despite some mildly bearish signals from KST and Dow Theory.

As of 4 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages confirm a bullish stance as well. However, the KST shows a mildly bearish signal on the weekly and monthly, and Dow Theory indicates a mildly bullish trend on the weekly with no trend on the monthly. Overall, the bullish indicators outweigh the bearish signals, suggesting a strong bullish sentiment in the current market for Bliss GVS Pharma.

When is the next results date for Bliss GVS Pharma Ltd?

The next results date for Bliss GVS Pharma Ltd is 10 February 2026.

The next results date for Bliss GVS Pharma Ltd is scheduled for 10 February 2026.

Why is Bliss GVS Pharma Ltd falling/rising?

As of 08-Feb, Bliss GVS Pharma Ltd's stock price is declining by -1.27% after four days of gains, indicating a potential trend reversal. Despite this drop, the stock has shown strong long-term performance, with a year-to-date increase of 12.02% and a significant outperformance compared to the benchmark Sensex.

As of 08-Feb, Bliss GVS Pharma Ltd's stock price is currently falling, as indicated by a change of -2.35, or -1.27%. This decline comes after a period of four consecutive days of gains, suggesting a trend reversal. The stock touched an intraday low of Rs 177.3, which represents a significant drop of -4.42% at its lowest point today. Additionally, the performance today has underperformed the sector by -0.47%.<BR><BR>Despite the current decline, the stock has shown strong performance over various periods, including a year-to-date increase of 12.02% and a one-year return of 19.16%. It has consistently outperformed the benchmark Sensex over the past year and three years, with a remarkable 149.18% increase over the last three years compared to the Sensex's 38.13%. <BR><BR>Moreover, the stock is trading above its moving averages, indicating a generally positive trend over the longer term. The rising investor participation, evidenced by a 45.71% increase in delivery volume on February 5, suggests that there is still interest in the stock despite today's decline. However, the current price drop may reflect a natural market correction after a period of gains, as well as the stock trading at a premium compared to its peers' average historical valuations.

Which are the latest news on Bliss GVS Pharma?